Prostate cancer (PCa) is one of the most commonly diagnosed malignancies and among the
leading causes of cancer-related death worldwide. It is a highly heterogeneous disease …

Motivation Platform designs-master protocols that allow for new treatment arms to be added
over time-have gained considerable attention in recent years. Between 2001 and 2019, 16 …

Background Multi-arm platform trials investigate multiple agents simultaneously, typically
with staggered entry and exit of experimental treatment arms versus a shared control arm. In …

Precision medicine has revolutionised cancer treatments; however, actionable biomarkers
remain scarce. To address this, we develop the Oncology Biomarker Discovery (OncoBird) …

The COVID-19 pandemic has led to an unprecedented response in terms of clinical
research activity. An important part of this research has been focused on randomized …

Background Platform trials can evaluate the efficacy of several experimental treatments
compared to a control. The number of experimental treatments is not fixed, as arms may be …

Rare diseases affect over 400 million people worldwide and less than 5% of rare diseases
have an approved treatment. Fortunately, the number of underlying disease etiologies is far …

It has been 100 years since the life-saving discovery of insulin, yet daily management of type
1 diabetes (T1D) remains challenging. Even with closed-loop systems, the prevailing need …

Importance Platform trials have become increasingly common, and evidence is needed to
determine how this trial design is actually applied in current research practice. Objective To …

The research and development (R&D) ecosystem has evolved over the past decade to
include pandemic infectious diseases, building on experience from multiple recent …